New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

The future of the weight loss market might not revolve around GLP-1 drugs.

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

The FDA has decided to reconsider its ban on drug compounders from making versions of Eli Lilly's weight loss and diabetes ...